Dicerna Pharmaceuticals (NASDAQ:DRNA) Upgraded by Zacks Investment Research to Buy

Dicerna Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Dicerna Pharmaceuticals Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Dicerna Pharmaceuticals traded up $0.75 on Tuesday, reaching $20.52. 0 shares of the stock traded hands, compared to its average volume of 836332. Shares of Dicerna Pharmaceuticals were trading at $20.52 on Tuesday. The firm’s 50 day moving average is $21.90 and its 200 day moving average is $27.52.Dicerna Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $40.14. While on yearly highs and lows, Dicerna Pharmaceuticals’s today has traded high as $20.63 and has touched $19.80 on the downward trend. See More Analyst Rating at: RATING

Dicerna Pharmaceuticals Earnings and What to expect: 

Dicerna Pharmaceuticals last issued its earnings results on August 9th, 2021. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of $0.51 by $1.04. The firm earned $41.34 million during the quarter, compared to analysts’ expectations of $129.44 million. Dicerna Pharmaceuticals has generated ($1.52) earnings per share over the last year (($1.70) diluted earnings per share). Earnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($1.70) to ($1.05) per share. Dicerna Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($1.70) to ($1.05) per share. The P/E ratio of Dicerna Pharmaceuticals is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Dicerna Pharmaceuticals is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Dicerna Pharmaceuticals has a P/B Ratio of 11.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Dicerna Pharmaceuticals (NASDAQ:DRNA) Moving Average Technical Analysis

5 day Moving Average is $19.89 And 5 day price change is $0.53 (2.65%)  with average volume for 5 day average is 487,180. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $20.43 and 20 day price change is -$0.62 (-2.93%) and average 20 day moving volume is 688,810. 50 day moving average is $21.90  and 50 day price change is -$16.42 ( -44.45%)  and with average volume for 50 days is : 1,111,698. 200 day moving average is $27.52  and 200 day price change is -$2.91 (-12.42%)  and with average volume for 200 days is : 845,186.

Other owners latest trading in Dicerna Pharmaceuticals :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 85,871 which equates to market value of $3.21M and appx 0.00% owners of Dicerna Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 1,112,089 which equates to market value of $41.50M and appx 0.00% owners of Dicerna Pharmaceuticals
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 72,371 which equates to market value of $2.70M and appx 0.00% owners of Dicerna Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 78.44% for Dicerna Pharmaceuticals

See More Analyst Rating at: RATING